Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

EMBRACE, eribulin, and new realities of advanced breast cancer.

Lin NU, Burstein HJ.

Lancet. 2011 Mar 12;377(9769):878-80. doi: 10.1016/S0140-6736(11)60280-8. Epub 2011 Mar 2. No abstract available.

PMID:
21376386
2.

Eribulin.

Perry CM.

Drugs. 2011 Jul 9;71(10):1321-31. doi: 10.2165/11207520-000000000-00000. Review.

PMID:
21770478
3.

Eribulin mesylate for the treatment of breast cancer.

Cigler T, Vahdat LT.

Expert Opin Pharmacother. 2010 Jun;11(9):1587-93. doi: 10.1517/14656566.2010.486790. Review.

PMID:
20450446
4.

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.

Scarpace SL.

Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25. Review.

PMID:
22739019
5.

Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.

McBride A, Butler SK.

Am J Health Syst Pharm. 2012 May 1;69(9):745-55. doi: 10.2146/ajhp110237. Review.

PMID:
22517020
6.

Eribulin mesylate for the treatment of late-stage breast cancer.

Gourmelon C, Frenel JS, Campone M.

Expert Opin Pharmacother. 2011 Dec;12(18):2883-90. doi: 10.1517/14656566.2011.637490. Epub 2011 Nov 17. Review.

PMID:
22087618
7.

Advances in therapy: eribulin improves survival for metastatic breast cancer.

Morris PG.

Anticancer Drugs. 2010 Nov;21(10):885-9. doi: 10.1097/CAD.0b013e32833ed62e. Review.

PMID:
20838209
8.

Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Polastro L, Aftimos PG, Awada A.

Expert Rev Anticancer Ther. 2014 Jun;14(6):649-65. doi: 10.1586/14737140.2014.920693. Review.

PMID:
24852360
9.

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Cortes J, Montero AJ, Glück S.

Cancer Treat Rev. 2012 Apr;38(2):143-51. doi: 10.1016/j.ctrv.2011.03.006. Epub 2011 May 8. Review.

PMID:
21550727
10.

[Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].

Koyama N, Tokunaga T, Ogasawara W, Murakami M, Yamashita Y.

Nihon Yakurigaku Zasshi. 2011 Nov;138(5):209-17. Review. Japanese. No abstract available.

PMID:
22075465
11.

The place for eribulin in the treatment of metastatic breast cancer.

Gradishar WJ.

Curr Oncol Rep. 2011 Feb;13(1):11-6. doi: 10.1007/s11912-010-0145-9. Review.

PMID:
21104168
12.

Eribulin mesylate.

Jain S, Vahdat LT.

Clin Cancer Res. 2011 Nov 1;17(21):6615-22. doi: 10.1158/1078-0432.CCR-11-1807. Epub 2011 Aug 22. Review.

13.

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?

Aftimos P, Awada A.

Adv Ther. 2011 Nov;28(11):973-85. doi: 10.1007/s12325-011-0070-9. Epub 2011 Oct 19. Review.

PMID:
22020735
14.

Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.

Saji S.

BioDrugs. 2013 Oct;27(5):469-78. doi: 10.1007/s40259-013-0038-1. Review. Erratum in: BioDrugs. 2013 Oct;27(5):541-3.

15.

Eribulin -- a review of preclinical and clinical studies.

Swami U, Chaudhary I, Ghalib MH, Goel S.

Crit Rev Oncol Hematol. 2012 Feb;81(2):163-84. doi: 10.1016/j.critrevonc.2011.03.002. Epub 2011 Apr 14. Review.

16.

Eribulin: a novel cytotoxic chemotherapy agent.

Preston JN, Trivedi MV.

Ann Pharmacother. 2012 Jun;46(6):802-11. doi: 10.1345/aph.1Q636. Epub 2012 May 22. Review.

PMID:
22619477
17.

Issues in the treatment of metastatic breast cancer.

Barse PM.

Semin Oncol Nurs. 2000 Aug;16(3):197-205. Review.

PMID:
10967792
18.

Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.

Dean-Colomb W, Esteva FJ.

Semin Oncol. 2008 Apr;35(2 Suppl 2):S31-8; quiz S40. doi: 10.1053/j.seminoncol.2008.02.008. Review.

PMID:
18410797
19.

Approved agents for metastatic breast cancer.

Fornier MN.

Semin Oncol. 2011 Jun;38 Suppl 2:S3-10. doi: 10.1053/j.seminoncol.2011.04.003. Review.

PMID:
21600382
20.

Novel anti-tubulin cytotoxic agents for breast cancer.

Morris PG, Fornier MN.

Expert Rev Anticancer Ther. 2009 Feb;9(2):175-85. doi: 10.1586/14737140.9.2.175. Review.

PMID:
19192956
Items per page

Supplemental Content

Write to the Help Desk